WuXi STA Expands Capabilities at Changzhou Campus
WuXi STA has added two reactors at its Changzhou campus in China, enhancing capacity and capability at its TIDES contract research, development and manufacturing platform for oligonucleotide, peptide and related synthetic conjugates. The reactors have capacity of 2,000 liters each, taking total volume for solid-phase peptide synthesizers to more than 10,000 liters.
The company has also added a new twin-column continuous purification system that can handle kilogram-scale peptides and oligonucleotides. WuXi STA said the continuous process enables a faster turnaround time and lower solvent consumption, allowing for more efficient and sustainable manufacturing.
CEO Minzhang Chen commented: " We are committed to continuously enhancing our WuXi TIDES CRDMO platform's capacity and capability to expedite the development and commercialization of more innovative therapies for patients worldwide."
In January, the company announced that its first drug product continuous manufacturing line for oral solids went into operation at its site in Wuxi City, China. Wuxi STA said the new line provides customers “an enhanced oral drug development solution that enables higher yields and a shorter time to market.
Author: Elaine Burridge, Freelance Journalist
